申请人:Abbott Laboratories
公开号:US04822811A1
公开(公告)日:1989-04-18
Compounds of the formula: ##STR1## wherein R1 is hydrogen, C1 to C4 alkyl, C2 to C4 alkenyl, or NR2R3, wherein R2 and R3 are independently selected from hydrogen, C1 to C4 alkyl and hydroxyl, but R2 and R3 are not simultaneously hydroxyl; X is oxygen, sulfur, CO2, or NR4, wherein R4 is hydrogen, C1 to C6 alkyl, C1 to C6 alkoyl or aroyl; A is selected from C1 to C6 alkylene and C2 to C6 alkenylene; Y is selected independently at each occurrence from hydrogen, halogen, hydroxy, cyano, nitro, halosubstituted alkyl, C1 to C12 alkyl, C2 to C12 alkenyl, C1 to C12 alkoxy, C3 to C8 cycloalkyl, aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, C1 to C12 arylthicalkoxy, and substituted derivatives of aryl, aryloxy, aroyl, C1 to C12 arylalkyl, C2 to C12 arylalkenyl, C1 to C12 arylalkoxy, or C1 to C12 arylthioalkoxy, wherein C12 alkyl, alkoxy, and halosubstituted alkyl; n is a number having the values 0-4; when n=0 then Y=hydrogen; and M is hydrogen, a pharmaceutically acceptable cation, aroyl, or C1 to C12 alkoyl. These compounds are potent inhibitors of 5- and/or 12-lipoxygenase enzymes. Also disclosed are lipoxygenase inhibiting compositions and a method of inhibiting lipoxygenase.
式为:##STR1## 其中 R1 为氢、C1 到 C4 烷基、C2 到 C4 烯基或 NR2R3,其中 R2 和 R3 分别选择自氢、C1 到 C4 烷基和羟基,但 R2 和 R3 不同时为羟基;X 为氧、硫、CO2 或 NR4,其中 R4 为氢、C1 到 C6 烷基、C1 到 C6 烷酰基或芳酰基;A 从 C1 到 C6 烷基和 C2 到 C6 烯基中选择;Y 在每次出现时独立选择自氢、卤素、羟基、氰基、硝基、卤代烷基、C1 到 C12 烷基、C2 到 C12 烯基、C1 到 C12 烷氧基、C3 到 C8 环烷基、芳基、芳氧基、芳酰基、C1 到 C12 芳基烷基、C2 到 C12 芳基烯基、C1 到 C12 芳基氧基、C1 到 C12 芳基硫基氧基和芳基、芳氧基、芳酰基、C1 到 C12 芳基烷基、C2 到 C12 芳基烯基、C1 到 C12 芳基氧基或 C1 到 C12 芳基硫基氧基的取代衍生物中选择,其中 C12 烷基、烷氧基和卤代烷基;n 为取值为 0-4 的数字;当 n=0 时,Y=氢;M 为氢、药学上可接受的阳离子、芳酰基或 C1 到 C12 烷酰基。这些化合物是 5- 和/或 12- 脂氧化酶酶的有效抑制剂。还公开了抑制脂氧化酶的组合物和抑制脂氧化酶的方法。